


The listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims:

1. (Previously Presented) A process for preparing tetrahydropterin of the following formula



or a tetrahydropterin compound of said tetrahydropterin that is substituted at the 6-, or 7- or 6- and 7- position or positions,

comprising hydrogenating pterin of the following formula



or a pterin compound of said pterin that is monosubstituted at the 6-, or 7- or 6- and 7- position or positions,

with hydrogen in a polar reaction medium in the presence of a hydrogenation catalyst that is a metal complex that is soluble in the reaction medium, wherein the catalyst contains a ligand which is (i) triarylpophosphine, (ii) tetramethylene phenylphosphine (iii) pentamethylene phenylphosphine, or (iv) a bidentate ligand with a tertiary amine group and a phosphine group or with two tertiary phosphine groups as complexing groups, wherein the bidentate ligands form together with a metal atom a five- to ten membered ring.


2. (Previously Presented) A process according to claim 1, wherein the polar reaction medium is an aqueous or alcoholic reaction medium.

3. (Previously Presented) A process according to claim 1, wherein the pterin compound is folic acid, a folic acid salt, a folic acid ester, a folic acid ester salt or a dihydro form thereof, with the proviso that in the event of using folic acid, a carboxylic acid thereof or a dihydro form thereof, the reaction medium is aqueous, and in the event of using a folic acid ester, a folic acid ester salt or a dihydro form thereof, the reaction medium is an alcohol.

4. (Previously Presented) A process according to claim 1, wherein the metal complex contains a chiral ligand.

5. (Previously Presented) A process according to claim 3, wherein the metal complex contains a chiral ligand.

6. (Previously Presented) A process according to claim 5, wherein the folic acid ester salt is of formula III and is in the form of a single enantiomer or a mixture of enantiomers of formula III,



in which

one of R₁ or R₂ is H, and the other one of R₁ or R₂ is a monovalent hydrocarbon radical or a hydrocarbon radical attached via a carbon atom in which one or more carbon atoms are each independently replaced by oxygen, sulfur, NH, -N=, or -N(C₁-C₄ Alkyl)-, or both R₁ and R₂ independently of one another represent a monovalent hydrocarbon radical or a hydrocarbon radical attached via a carbon atom in which one or more carbon atoms are each independently replaced by oxygen, sulfur, NH, -N=, or -N(C₁-C₄ Alkyl)-,

HA stands for a monobasic to tribasic inorganic or organic acid, and

x denotes an integer from 1 to 6 or a fractional number between 0 and 6.

7. (Previously Presented) A process according to claim 6, wherein HA is unsubstituted or substituted phenylsulphonic acid.

8. (Previously Presented) A process according to claim 1, wherein said process is carried out at a hydrogen pressure of 1 to 500 bars.

9. (Previously Presented) A process according to claim 1, wherein said process is carried out at a temperature is 0 to 150⁰C.


10. (Previously Presented) A process according to claim 1, wherein the molar ratio of pterin or pterin compound to catalyst is 10 to 100,000.

11. (Previously Presented) A process according to claim 1, wherein the reaction medium is water or water in admixture with an organic solvent.


12. (Previously Presented) A process according to claim 2, wherein the alcoholic reaction medium is an alcohol, or an alcohol in admixture with an organic solvent.

13. (Previously Presented) A process according to claim 1, wherein the metal complex contains a d-8 metal.

14. (Currently Amended) A process for preparing tetrahydropterin of the following formula



or a tetrahydropterin compound of said tetrahydropterin that is substituted at the 6-, or 7- or 6- and 7- position or positions,
comprising hydrogenating pterin of the following formula



or a pterin compound of said pterin that is monosubstituted at the 6-, or 7- or 6- and 7- position or positions,

with hydrogen in a polar reaction medium in the presence of a hydrogenation catalyst that is a metal complex that is soluble in the reaction medium, wherein





the catalyst has a ligand that is of formula IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, XL, Y1 or Y2,



in which





R_4 , R_5 , R_7 and R_8 independently of one another represent a hydrocarbon radical with 1 to 20 carbon atoms which are unsubstituted or substituted with halogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₆-haloalkoxy, (C₆H₅)₃Si, (C₁-C₁₂-alkyl)₃Si, -NH₂, -NH(C₁-C₁₂-alkyl), -NH(phenyl), -NH(benzyl), -N(C₁-C₁₂-alkyl)₂, -N(phenyl)₂, -N(benzyl)₂, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, -ammonium-X₃⁻, -SO₃M₁, -CO₂M₁, -PO₃(M₁)₂, -PO₃M₁, or -CO₂-C₁-C₆-alkyl, where M₁ represents an alkali metal or hydrogen, and X₃⁻ is an anion of a monobasic acid; or R₄ and R₅ and/or R₇ and R₈ together denote tetramethylene, pentamethylene or 3-oxa-pentane-1,5-diyl, unsubstituted or substituted with halogen, C₁-C₆-alkyl or C₁-C₆-alkoxy, and







R₆ is C₂-C₄-alkylene, unsubstituted or substituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, C₅-cycloalkyl or C₆-cycloalkyl, phenyl, naphthyl or benzyl; 1,2- or 1,3-cycloalkylene, 1,2- or 1,3-cycloalkenylene, 1,2- or 1,3-bicycloalkylene or 1,2- or 1,3-bicycloalkenylene with 4 to 10 carbon atoms, unsubstituted or substituted with C₁-C₆-alkyl, phenyl or benzyl; 1,2- or 1,3-cycloalkylene, 1,2- or 1,3-cycloalkenylene, 1,2- or 1,3-bicycloalkylene or 1,2- or 1,3-bicycloalkenylene with 4 to 10 carbon atoms, unsubstituted or substituted with C₁-C₆-alkyl, phenyl or benzyl, and attached at whose 1- and/or 2-position(s) or at whose 3-position is methylene or C₂-C₄-alkylidene; 1,4-butylene, substituted in the 2,3-positions with R₉-R₁₀C(O-)₂, and in the 1- and/or 4-positions unsubstituted or substituted with C₁-C₆-alkyl, phenyl or benzyl, and where R₉ and R₁₀ independently of one another represent hydrogen, C₁-C₆-alkyl, phenyl or benzyl; 3,4- or 2,4-pyrrolidinylene or methylene-4-pyrrolidine-4-yl, the N-Atom of which is substituted with hydrogen, C₁-C₁₂-alkyl, phenyl, benzyl, C₁-C₁₂-alkoxycarbonyl, C₁-C₈-acyl, C₁-C₁₂-alkylamino carbonyl; or 1,2-phenylene, 2-benzenylene, 1,2-xylylene, 1,8-naphthylene, 2,2'-dinaphthylene or 2,2'-diphenylene, unsubstituted or substituted with halogen, -OH, C₁-C₆-alkyl, C₁-C₆-alkoxy, phenyl, benzyl, phenoxy or benzyloxy; or R₆ stands for a radical of one of the following formulas



in which

R_9 denotes hydrogen, C₁-C₈-alkyl, C₁-C₄-fluoroalkyl, unsubstituted phenyl or phenyl substituted with 1 to 3 F, Cl, Br, C₁-C₄-alkyl, C₁-C₄-alkoxy or fluoromethyl;





in which

R₄, R₅ R₇ and R₈ have the meanings as recited above,

R₁₀ and R₁₁ independently of one another denote hydrogen, C₁-C₄ alkyl or benzyl or

phenyl, unsubstituted or substituted with one to three C₁-C₄ alkyl or C₁-C₄ alkoxy,

R_{12} and R_{13} independently of one another represent hydrogen, C₁-C₄ alkyl, phenyl or benzyl,

R_{14} and R_{15} independently of one another denote hydrogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, or benzyl or phenyl, unsubstituted or substituted with one to three C₁-C₄ alkyl or C₁-C₄ alkoxy,

R_{16} represents hydrogen, C₁-C₁₂ alkyl, unsubstituted benzyl or phenyl, or benzyl or phenyl substituted with one to three C₁-C₄ alkyl or C₁-C₄ alkoxy, C₁-C₁₂ alkoxy-C(O)-, unsubstituted phenyl-C(O)- or benzyl-C(O)-, or phenyl-C(O)- or benzyl-C(O)- substituted with one to three C₁-C₄ alkyl or C₁-C₄ alkoxy, C₁-C₁₂ alkyl-NH-CO-, or phenyl-NH-C(O)- or benzyl-NH-C(O)-, unsubstituted or substituted with one to three C₁-C₄ alkyl or C₁-C₄ alkoxy,

n stands for 0, 1 or 2,


R_{17} and R_{18} are C₁-C₄ alkyl or C₁-C₄ alkoxy, or R_{17} and R_{18} together denote oxadimethylene,

R_{19} , R_{20} , R_{21} , R_{22} , R_{23} and R_{24} are independently of one another H, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₅- or C₆ cycloalkyl or C₅- or C₆ cycloalkoxy, phenyl, benzyl, phenoxy, benzyloxy, halogen, OH, -(CH₂)₃-C(O)-O-C₁-C₄ alkyl, -(CH₂)₃-C(O)-N(C₁-C₄-alkyl)₂ or -N(C₁-C₄-alkyl)₂, or R_{19} and R_{21} , and/or R_{17} and R_{21} , and/or R_{20} and R_{22} , and/or R_{18} and R_{22} , or R_{21} and R_{23} and/or R_{22} and R_{24} together represent a fused-on 5 or 6-membered, monocyclic or bicyclic hydrocarbon ring, and


R_{25} is C₁-C₄ alkyl;




(XXIV),




(XXV),




(XXVI),




(XXVII),




(XXVIII),




(XXIX) (XXIX),




(XXX),




(XXXI),




(XXXII),




(XXXIII),




(XXXIV),




(XXXV),




(XXXVI),




(XXXVII),



(XXXVIII),



(XXXIX)




, (XL),


in which

R stands for cyclohexyl or unsubstituted phenyl or phenyl substituted with one to three C₁-C₄-alkyl, C₁-C₄-alkoxy, trifluoromethyl, or an -NH₂ (C₁-C₄-alkyl)NH-, (C₁-C₄-alkyl)₂N-, R₂₆ and R₂₇ independently of one another denote C₁-C₄-alkyl, phenyl or benzyl, R₂₈ represents C₁-C₈-alkyl, C₁-C₈-acyl or C₁-C₈-alkoxycarbonyl, R₂₉ stands for hydrogen, C₁-C₄-alkyl, phenyl or benzyl, R₃₀ represents C₁-C₄-alkyl, phenyl or benzyl, R₃₁ denotes methyl, methoxy, or both R₃₁ together denote oxadimethylene, R₃₂ and R₃₃ independently of one another represent H, C₁-C₄-alkyl, C₁-C₄-alkoxy or (C₁-C₄-alkyl)₂N-, R₃₄ and R₃₅ independently of one another represent H, C₁-C₄-alkyl, C₁-C₄-alkoxy,

$-(CH_2)_3-C(O)-O-C_1-C_4\text{-alkyl}$, $-(CH_2)_3-C(O)-N(C_1-C_4\text{-alkyl})_2$ or one pair R_{34} and R_{35} together represents a radical of formula XLI and the other pair R_{34} and R_{35} together represents a radical of formula XLII





(XLI),



(XLII),

and

R_{36} stands for $C_1-C_4\text{-alkyl}$,




wherein R_{111} and R_{112} are each independently H or methyl.

15-28. (Cancelled)

29. (Previously Presented)


A process for preparing tetrahydropterin of

the following formula



or a tetrahydropterin compound of said tetrahydropterin that is substituted at the 6-, or 7- or 6- and 7- position or positions,

comprising hydrogenating pterin of the following formula



or a pterin compound of said pterin that is monosubstituted at the 6-, or 7- or 6- and 7- position or positions,

with hydrogen in alcohol or in alcohol in admixture with an organic solvent in the presence of a hydrogenation catalyst that is a metal complex that is soluble in the reaction medium.

30-32. (Cancelled)

33. (Previously Presented)

A process according to claim 3, wherein the


hydrogenation is carried out at elevated pressure.

34. (Previously Presented) A process according to claim 1, wherein the metal complex contains iridium, rhodium or ruthenium.


35-36. (Cancelled)

37-39. (Cancelled)

40. (Previously Presented) A process for preparing tetrahydropterin of the following formula



or a tetrahydropterin compound of said tetrahydropterin that is substituted at the 6-, or 7- or 6- and 7- position or positions,
comprising hydrogenating pterin of the following formula




or a pterin compound of said pterin that is monosubstituted at the 6-, or 7- or 6- and 7- position or positions,
with hydrogen in alcohol or in alcohol in admixture with an organic solvent in the presence of a hydrogenation catalyst that is a metal complex that is soluble in the reaction medium, wherein

the pterin compound is folic acid, a folic acid salt, a folic acid ester, a folic acid ester salt or a dihydro form thereof, with the proviso that in the event of using folic acid, a carboxylic acid thereof or a dihydro form thereof, the reaction medium is aqueous, and in the event of using a folic acid ester, a folic acid ester salt or a dihydro form thereof, the reaction medium is an alcohol.

41-44. (Cancelled)

45. (Previously Presented) A process according to claim 1, wherein the pterin compound is a pterin that is substituted in the 6- position.

46. (Previously Presented) A process according to claim 1, wherein the pterin compound is of formula (A)



in which

R₁₀₁ is H or independently has the meaning of R₁₀₀, and

R₁₀₀ is an organic radical attached via a C, O or N atom and having 1 to 50 carbon atoms.

47. (Previously Presented) A process according to claim 46, wherein R₁₀₀ contains 1 to 30 carbon atoms and is not interrupted or is interrupted by one or more of -O-, -NH-, -N(C₁-C₄-alkyl)-, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NH-, -NHC(O)-, -NHC(O)O-, -OC(O)NH-, -NHC(O)NH-, -C(O)N(C₁-C₄-alkyl)-, -N(C₁-C₄-alkyl)C(O)-, -N(C₄-alkyl)C(O)O-, -OC(O)N(C₁-C₄-alkyl)-, -N(C₁-C₄-alkyl)C(O)N(C₁-C₄-alkyl)-, and which is unsubstituted or is substituted with F, Cl, Br, -CN, -OCN, -NCO, -OH, -NH₂, -NHC₁-C₄-alkyl, -


N(C₁-C₄-alkyl)₂, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, -C(O)OH, -C(O)OM₁₀₀, -C(O)OC₁-C₄-alkyl, -C(O)NH₂, -C(O)NHC₁-C₄-alkyl, -C(O)N(C₁-C₄-alkyl)₂, R₁₀₂-C(O)O-, R₁₀₂-OC(O)O-, R₁₀₂-C(O)NH-, R₁₀₂-C(O)N(C₁-C₄-alkyl)-, R₁₀₂-NHC(O)NH-, R₁₀₃C(O)- or -CH(O), wherein

M₁₀₀ is Li, K, Na, NH₄⁺, or ammonium with 1 to 16 carbon atoms,

R₁₀₂ is C₁-C₈-alkyl, C₅- or C₆-cycloalkyl, phenyl or benzyl, and


R₁₀₃ is C₁-C₄-alkyl, phenyl or benzyl.

48. (Previously Presented) A process for preparing tetrahydropterin of the following formula



or a tetrahydropterin compound of said tetrahydropterin that is substituted at the 6-, or 7- or 6- and 7- position or positions,

comprising hydrogenating pterin of the following formula



or a pterin compound of said pterin that is monosubstituted at the 6-, or 7- or 6- and 7- position or positions,

with hydrogen in a polar reaction medium in the presence of a hydrogenation catalyst that is a metal complex that is soluble in the reaction medium of formula XLIV, XLIVa or XLIVb,



in which

Y stands for monoolefin ligands or a diene ligand;

X_7 represents an achiral or chiral ditertiary diphosphine, that forms a 5 to 7 membered ring with the metal atom Me_2 or Ru;

X_7 represents an achiral or chiral ligand that forms a 5 to 7 membered ring with the metal atom Me_2 or Ru, wherein said ligand contains two tertiary phosphine groups;

Me_2 denotes Ir(I) or Rh(I);

Z represents -Cl, -Br, or -I; and

A_2 is ClO_4^- , CF_3SO_3^- , CH_3SO_3^- , HSO_4^- , BF_4^- , $\text{B}(\text{Phenyl})_4^-$, PF_6^- , SbCl_6^- , AsF_6^- or SbF_6^- ;

X_8 and X_9 are the same or different and have the meaning of Z or A_2 , or X_8 has the meaning of Z or A_2 and X_9 stands for hydride.

49. (Previously Presented) A process according to claim 6, wherein R_1 and/or R_2 are, each independently,

pyrrolidinyl, piperidinyl, morpholinyl, tetrahydropyranyl, piperazinyl, pyrrolidinyl methyl, pyrrolidinyl ethyl, piperidinyl methyl, piperidinyl ethyl, morpholinyl methyl, morpholinyl ethyl, tetrahydropyranyl methyl, tetrahydropyranyl ethyl, piperazinyl methyl or piperazinyl ethyl.

50. (Cancelled)

51. (Previously Presented) A process according to claim 14, wherein the catalyst has a ligand that is of formula Y1 or Y2.

52. (Previously Presented) A process according to claim 14, wherein the reaction medium is an alcoholic reaction medium.

53. (Previously Presented) A process according to claim 14, wherein the reaction medium is an aqueous reaction medium.

54. (Previously Presented) A process according to claim 14, wherein the catalyst has a ligand that contains one or more water-solubilising polar substituents.

55. (Previously Presented) A process according to claim 14, wherein the catalyst has a ligand that is of formula IV.

56. (Currently Amended) A process according to claim 14, wherein the catalyst has a ligand that is of formula V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII or XXIII.

57. (Previously Presented) A process according to claim 14, wherein the catalyst has a ligand that is of formula XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XXXI, XXXII, XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, or XL.